日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Eli Lilly plans to introduce its weight loss drug in China soon

By Zhou Wenting | chinadaily.com.cn | Updated: 2024-12-06 19:24
Share
Share - WeChat
The booth of US pharmaceutical company Eli Lilly and Co at the seventh China International Import Expo held in Shanghai in November 2024. [Photo provided to chinadaily.com.cn]

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its innovative weight loss therapy available to patients in China very soon.

"At Lilly, we're committed to supporting individuals affected by obesity, which is a chronic disease that requires effective treatment options and long-term management," said Huzur Devletsah, president and general manager of Lilly China.

Her comment came after Lilly announced the top-line results from the SURMOUNT-5 clinical trial that day, showing that its Zepbound (tirzepatide) provided a 47 percent greater relative weight loss compared to Wegovy (semaglutide) by Danish pharmaceutical company Novo Nordisk.

Wegovy was marketed earlier than Zepbound, and is currently the world's best-selling GLP-1 weight loss medicine.

Lilly said the trial results showed that on average, Zepbound led to a weight loss of 20.2 percent compared to 13.7 percent with Wegovy. A key competitiveness of Zepbound lies in that it is the only US FDA-approved product that activates both GLP-1 and GIP - two receptors playing key roles in regulating blood sugar and energy balance in the human body.

GLP-1 therapies, originally used to treat type 2 diabetes, have gained popularity throughout the world due to their weight loss effect in recent years. Novo Nordisk and Lilly are currently the main global leaders.

The companies' financial reports showed that in the first three quarters of this year, Wegovy's revenue was about $5.53 billion, a year-on-year increase of 77 percent, and Zepbound's revenue was nearly $3.02 billion after the figure exceeded $1 billion for the first time in the second quarter.

British bank Barclays predicted that the global weight loss therapy market will grow to $150 billion by 2030. And according to the forecast of US consultancy Frost & Sullivan, the market size of GLP-1 medicines in China will exceed 50 billion yuan in 2030.

Domestic medical experts said that such positive trial results may affect doctors' drug recommendations in clinical use, but which therapies to prescribe may be affected by multiple factors, including indications, prices, reimbursement policies, and patient preferences.

In October, Lilly announced a roughly $200 million expansion of its manufacturing site in Suzhou, Jiangsu province, aiming to increase production of such innovative medicines.

During a previous interview with media outlet ThePaper.cn, Zhou Xiaping, global senior vice-president of Novo Nordisk and president of Novo Nordisk China, said that with full confidence in its products, the company welcomes healthy competition in the field of GLP-1 medicines to jointly help more obese patients.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 激情综合婷婷久久 | 欧美极品欧美精品欧美视频 | 久久爱成人网 | 国产成人综合一区二区三区 | 日本喷潮 | www.alijizz.info| 国产在线激情 | 国产精品免费av | 9久9久女女热精品视频免费观看 | a级片在线免费观看 | 天天操很很操 | 国产欧美一区二区三区另类精品 | 欧美特黄aaaaaa | 欧美成人在线免费观看 | 日本一区二区三区免费观看 | 欧美性爽xxxⅹbbbb | 成人黄色免费在线观看 | 妖精视频国产 | 久草中文在线 | 久久大胆视频 | 91视频高清 | 91青青国产在线观看免费 | 奇米色偷偷 | 久久这里只有精品免费看青草 | 久久国产高清 | 最新国产精品 | 精品久久网 | 成人在线免费网站 | 一级毛片在线观看视频 | 精品国产AV色一区二区深夜久久 | 欧美日韩不卡合集视频 | 亚洲AV久久久噜噜噜久久 | 中文在线一区二区 | 99热这里| 国产成人精品视频免费 | 午夜家庭影院 | 精品久久九九 | 久久精品一 | 丝袜 亚洲 另类 欧美 综合 | 久久91| 四月婷婷七月婷婷综合 |